A short cut review was carried out to establish whether intravenous dexrazoxane reduces the risk of tissue necrosis after extravasation of the chemotherapy agent anthracycline. One paper directly addressed the question. The clinical bottom line is that intravenous dexrazoxane appears to be safe and may reduce the risk of tissue necrosis after extravasation of anthracycline.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.